Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.59 (market cap $6.04B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| HALO | IOVA | |
|---|---|---|
Market Cap | $12.58B | $6.04B |
Volume | 2,179,278 | 14,805,993 |
Sector | Health | Health |
52-Week High | $115.22 | $14.82 |
52-Week Low | $61.63 | $1.81 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $14.49B | $5.97B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
